局部使用0.05%环孢素A滴眼液联合0.3%玻璃酸钠滴眼液治疗干眼症的疗效分析

Analysis of the Efficacy of Local Use of 0.05% Cyclosporine A Eye Drops Combined with 0.3% Sodium Hyaluronate Eye Drops in the Treatment of Dry Eye Syndrome

摘要: 研究目的：评估0.05%环孢素A滴眼液每日两次联合0.3%玻璃酸钠滴眼液每日四次连续使用3个月治疗干眼症的疗效。研究方法：门诊纳入符合研究标准的14例干眼患者，使用0.05%环孢素A滴眼液每日2次联合0.3%玻璃酸钠滴眼液每日4次，连续使用3个月。分别在基线、用药后1.5个月和用药后3个月时评估主观症状和客观体征，包括中国干眼问卷量表(CDEQ)、泪液分泌II试验(Schirmer’s II test)、下方角膜荧光素染色评分(ICSS)、荧光素染色泪膜破裂时间(FBUT)、非侵入性平均泪膜破裂时间(NITBUT-av)、泪河高度(TMH)和眼红指数(ORI)，研究结果做自身前后对照。研究结果：连续治疗一个半月后，与用药前相比，CDEQ (P = 0.658)，Schirmer’s II test (P = 0.076)，TMH (P = 0.473)，NTBUT-av (P = 0.211)和ORI (P = 707)数值差异无统计学意义，而FBUT (P = 0.008)和ICSS (P = 0.003)与用药前的差异具有统计学意义。连续治疗三个月后，与用药前相比，CDEQ (P = 0.007)，Schirmer’s II test (P = 0.009)，FBUT (P = 0.008)和ICSS (P < 0.001)的数值差异具有统计学意义，而TMH (P = 0.182)，NTBUT-av (P = 0.080)和ORI (P = 0.337)数值差异无统计学意义。治疗三个月与治疗一个半月时相比，仅有ORI (P = 0.041)的数值差异具有统计学意义。所有患者在治疗过程中，均未出现明显不良反应。研究结论：局部使用0.05%环孢素A滴眼液联合0.3%玻璃酸钠滴眼液，能有效提高干眼症患者的泪膜稳定性并改善主观不适症状。

Abstract: Purpose: To evaluate the efficacy of 0.05% cyclosporine A eye drops twice a day combined with 0.3% sodium hyaluronate eye drops four times a day for three months in the treatment of dry eye. Meth-od: 14 dry eye patients who met the research criteria were included in the outpatient department. 0.05% cyclosporine A eye drops were used twice a day in combination with 0.3% sodium hyalu-ronate eye drops four times a day for three consecutive months. Subjective symptoms and objective signs were evaluated at baseline, 1.5 months after medication, and 3 months after medication, in-cluding the Chinese Dry Eye Questionnaire (CDEQ), Tear Secretion II Test (Schirmer’s II test), Lower Corneal Fluorescein Staining Score (ICSS), Fluorescein Stained Tear Film Rupture Time (FBUT), Non Invasive Mean Tear Film Rupture Time (NITBUT-av), Tear River Height (TMH), and Eye Red Index (ORI), and compare the research results before and after the study. Results: After continuous treatment for one and a half months, there was no statistically significant difference in CDEQ (P = 0.658), Schirmer’s II test (P = 0.076), TMH (P = 0.473), NTBUT-av (P = 0.211), and ORI (P = 707) values compared to before medication, while FBUT (P = 0.008) and ICSS (P = 0.003) showed statis-tically significant differences compared to before medication. After three months of continuous treatment, there were statistically significant differences in the values of CDEQ (P = 0.007), Schirm-er’s II test (P = 0.009), FBUT (P = 0.008), and ICSS (P < 0.001) compared to before treatment, while there was no statistically significant difference in the values of TMH (P = 0.182), NTBUT-av (P = 0.080), and ORI (P = 0.337). Compared with one and a half months of treatment, only the numerical difference in ORI (P = 0.041) was statistically significant after three months of treatment. All pa-tients did not experience any significant adverse reactions during the treatment process. Conclu-sion: Local use of 0.05% cyclosporine A eye drops combined with 0.3% sodium hyaluronate eye drops can effectively improve tear film stability and subjective discomfort symptoms in dry eye pa-tients.